Investigational drug · Phase 2
MCLA-129
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-Small Cell Lung Cancer, Solid Tumor, Head and Neck Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
5
Any phase or sponsor naming "MCLA-129"
First trial start
2021
Sep 24, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MCLA-129", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-Small Cell Lung Cancer
- Solid Tumor
- Head and Neck Cancer
- Colorectal Cancer
- Solid Advanced Tumor
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Colorectal cancer · Head and neck cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "MCLA-129" as an intervention, largest first.
Betta Pharmaceuticals Co., Ltd.Industry
NCT04930432 · 400 participants (planned) · Start Sep 24, 2021 · Primary completion Apr 30, 2028
Drug: MCLA-129 · For: Solid Tumor; Non-Small Cell Lung Cancer; Head and Neck Cancer and 1 more
Sites: Baoding, China; Beijing, China; Bengbu, China · 87 sites in all
Merus B.V.Industry
NCT04868877 · 194 participants · Start Apr 28, 2021 · Primary completion Oct 1, 2026
Drug: MCLA-129; Osimertinib and 1 more · For: Non-Small Cell Lung Cancer Metastatic; Gastric Cancer; Esophageal Squamous Cell Carcinoma and 2 more
Sites: Orange, California; Nashville, Tennessee; West Valley City, Utah · 51 sites in all
- Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive MutationNot yet recruiting
Betta Pharmaceuticals Co., Ltd.Industry
NCT06015568 · 172 participants (planned) · Start Sep 1, 2023 · Primary completion Nov 4, 2028
Drug: MCLA-129: 1500mg or 2000mg IV Q2W; Befotertinib: 75 mg or 100 mg Po QD · For: Non-Small Cell Lung Cancer、EGFR Sensitive Mutation
Sites: Bengbu, China; Changsha, China; Shanghai, China
Betta Pharmaceuticals Co., Ltd.Industry
NCT07448116 · 164 participants (planned) · Start Jan 31, 2026 · Primary completion Feb 1, 2029
Drug: MCLA-129; Ensartinib · For: Solid Advanced Tumor
Sites: Beijing, China
- Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.Not yet recruiting
Betta Pharmaceuticals Co., Ltd.Industry
NCT06885840 · 100 participants (planned) · Start Mar 31, 2025 · Primary completion Apr 2028
Drug: MCLA-129 · For: Non-Small Cell Lung Cancer
Sites: Hefei, China; Lanzhou, China; Dongguan, China · 20 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Non-Small Cell Lung Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.